Skip to main content
. Author manuscript; available in PMC: 2019 Feb 15.
Published in final edited form as: Adv Drug Deliv Rev. 2018 Jan 13;126:67–95. doi: 10.1016/j.addr.2018.01.008

Fig. 11.

Fig. 11

(A) The log of the equilibrium association constant KA at pH 6.0 are plotted for various engineered anti-VEGF (bevacizumab) variants demonstrating increased binding to human FcRn in contrast to parent bevacizumab native IgG1 antibody; (B) Binding sensorgrams at pH 6.0 and 7.4 of each variant; Log-linear changes in serum concentrations for anti-VEGF (bevacizumab) and anti-EGFR antibodies in cynomolgus monkeys (C) and hFcRn transgenic mice (D) demonstrating antibodies engineered for higher FcRn affinity (Xtend-VEGF and Xtend-EGFR) promotes half-life extension. Reprinted from [96].